Baxter announced that the FDA has approved Feiba (anti-inhibitor coagulant complex [AICC]) for use as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with ...

Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only ...

The US Food and Drug Administration (FDA) has approved a new indication for Baxter's anti-inhibitor coagulant complex FEIBA as the first-ever routine prophylaxis to prevent bleeding in patients with ...

Pivotal study to form basis for upcoming biologic license application to the U.S. FDA DEERFIELD, Ill., JANUARY 8, 2013 - Baxter International Inc. (NYSE:BAX) today announced pivotal Phase III study ...

FEIBA is the first and only FDA-approved treatment for routine prophylaxis that controls the frequency of bleeding episodes in hemophilia A or B patients, who have developed inhibitors. Inhibitors are ...

DEERFIELD, Ill.--Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using FEIBA NF? FEIBA NF contains the active ingredient ...

FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX.